About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596
Debt
Debt-to-Equity Ratio0.34%
Current Ratio3.10%
Quick Ratio2.62%
Price-To-Earnings
Trailing P/E Ratio21.62
Forward P/E Ratio18.24
P/E Growth1.01
Sales & Book Value
Annual Sales$3.55 billion
Price / Sales6.99
Cash Flow$7.9170 per share
Price / Cash14.10
Book Value$39.81 per share
Price / Book2.80
Profitability
EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins12.48%
Return on Equity12.94%
Return on Assets8.50%
Miscellaneous
Employees2,525
Outstanding Shares222,360,000
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
How will Alexion Pharmaceuticals' stock buyback program work?
Alexion Pharmaceuticals announced that its board has authorized a stock buyback plan on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its stock is undervalued.
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals (NASDAQ:ALXN) released its quarterly earnings results on Thursday, February, 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $0.39. The biopharmaceutical company had revenue of $909.70 million for the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm's revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 EPS. View Alexion Pharmaceuticals' Earnings History.
When is Alexion Pharmaceuticals' next earnings date?
What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?
Alexion Pharmaceuticals issued an update on its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $6.60-6.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.03. The company issued revenue guidance of $3.85-3.95 billion, compared to the consensus revenue estimate of $4.06 billion.
What price target have analysts set for ALXN?
21 brokers have issued 12 month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $120.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $156.5238 in the next twelve months. View Analyst Ratings for Alexion Pharmaceuticals.
What are Wall Street analysts saying about Alexion Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. The prospects of ALXN1210 looks good too and a tentative approval will boost the top-line. Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease, a rare genetic disorder. Earlier, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics among others. Shares of the company have performed better than the industry in the last three months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also hit sales." (4/19/2018)
- 2. JPMorgan Chase analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Nektar Therapeutics (NKTR), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ) and BeiGene (BGNE).
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the folowing people:
- Dr. Ludwig N. Hantson, CEO & Director (Age 55)
- Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
- Ms. Julie O'Neill MBA, Exec. VP of Global Operations (Age 62)
- Mr. John B. Moriarty Jr., Former Exec. VP & Gen. Counsel (Age 50)
- Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)
Has Alexion Pharmaceuticals been receiving favorable news coverage?
Media headlines about ALXN stock have trended somewhat negative recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of -0.03 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 47.01 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Alexion Pharmaceuticals?
Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexion Pharmaceuticals' stock price today?
One share of ALXN stock can currently be purchased for approximately $111.66.
How big of a company is Alexion Pharmaceuticals?
Alexion Pharmaceuticals has a market capitalization of $25.19 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.
How can I contact Alexion Pharmaceuticals?
Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.
MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
21 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $156.5238, suggesting that the stock has a possible upside of 40.22%. The high price target for ALXN is $180.00 and the low price target for ALXN is $120.00. There are currently 1 hold rating and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Buy | Buy | Buy | Buy |
Consensus Rating Score: | 2.95 | 2.95 | 2.90 | 2.83 |
Ratings Breakdown: | 0 Sell Rating(s) 1 Hold Rating(s) 20 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 1 Hold Rating(s) 21 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 19 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 5 Hold Rating(s) 17 Buy Rating(s) 1 Strong Buy Rating(s) |
Consensus Price Target: | $156.5238 | $155.7273 | $153.55 | $154.8182 |
Price Target Upside: | 40.22% upside | 19.16% upside | 25.74% upside | 8.40% upside |
Alexion Pharmaceuticals (NASDAQ:ALXN) Consensus Price Target History

Alexion Pharmaceuticals (NASDAQ:ALXN) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Alexion Pharmaceuticals (NASDAQ:ALXN) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 95.09%
Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
2/28/2018 | Heidi L Wagner | SVP | Sell | 698 | $119.35 | $83,306.30 | | |
2/28/2018 | Julie O'neill | EVP | Sell | 1,625 | $119.83 | $194,723.75 | | |
2/8/2018 | Heidi L Wagner | SVP | Sell | 1,774 | $116.31 | $206,333.94 | 47,212 | |
2/8/2018 | John B Moriarty | EVP | Sell | 3,363 | $115.70 | $389,099.10 | 71,400 | |
2/8/2018 | Ludwig Hantson | CEO | Sell | 13,245 | $116.31 | $1,540,525.95 | 131,425 | |
2/8/2018 | Paul J Clancy | CFO | Sell | 6,079 | $116.31 | $707,048.49 | 95,093 | |
2/5/2018 | Heidi L Wagner | SVP | Sell | 655 | $117.26 | $76,805.30 | 32,635 | |
2/5/2018 | John B Moriarty | EVP | Sell | 1,261 | $117.26 | $147,864.86 | 20,210 | |
1/2/2018 | Ludwig Hantson | CEO | Sell | 2,553 | $121.63 | $310,521.39 | 36,172 | |
10/2/2017 | Heidi L Wagner | SVP | Sell | 120 | $140.00 | $16,800.00 | | |
9/5/2017 | Ann M Veneman | Director | Sell | 835 | $145.81 | $121,751.35 | 5,480 | |
9/5/2017 | Julie O'neill | EVP | Sell | 4,375 | $145.44 | $636,300.00 | 26,092 | |
8/28/2017 | Julie O'neill | EVP | Sell | 11,160 | $140.00 | $1,562,400.00 | 26,704 | |
7/31/2017 | Ann M Veneman | Director | Sell | 700 | $137.74 | $96,418.00 | 6,315 | |
6/15/2017 | Bros. Advisors Lp Baker | Director | Buy | 660,779 | $117.33 | $77,529,200.07 | | |
6/14/2017 | Bros. Advisors Lp Baker | Director | Buy | 1,348,955 | $116.32 | $156,910,445.60 | | |
6/14/2017 | Ludwig Hantson | CEO | Buy | 10,000 | $116.72 | $1,167,200.00 | 38,725 | |
3/1/2017 | Clare Carmichael | EVP | Sell | 2,179 | $131.66 | $286,887.14 | 33,980 | |
3/1/2017 | Heidi L Wagner | SVP | Sell | 994 | $131.65 | $130,860.10 | 29,646 | |
3/1/2017 | Leonard Bell | Director | Sell | 3,978 | $131.96 | $524,936.88 | 391,910 | |
2/28/2017 | Carsten Thiel | EVP | Sell | 125 | $74.52 | $9,315.00 | 30,197 | |
2/28/2017 | Edward Miller | SVP | Sell | 590 | $131.48 | $77,573.20 | 15,214 | |
2/28/2017 | Leonard Bell | Director | Sell | 2,738 | $131.71 | $360,621.98 | 391,910 | |
2/27/2017 | Edward Miller | SVP | Sell | 260 | $131.20 | $34,112.00 | 15,214 | |
2/27/2017 | John B Moriarty | EVP | Sell | 612 | $131.20 | $80,294.40 | 45,864 | |
2/9/2017 | John B Moriarty | EVP | Sell | 167 | $126.84 | $21,182.28 | 46,476 | |
2/9/2017 | Leonard Bell | Director | Sell | 246 | $126.84 | $31,202.64 | 394,648 | |
2/7/2017 | Heidi L Wagner | SVP | Sell | 1,932 | $125.97 | $243,374.04 | 30,241 | |
2/7/2017 | John B Moriarty | EVP | Sell | 3,538 | $125.79 | $445,045.02 | 46,801 | |
2/7/2017 | Leonard Bell | Director | Sell | 8,725 | $125.97 | $1,099,088.25 | 395,979 | |
1/10/2017 | Leonard Bell | Director | Sell | 100 | $144.99 | $14,499.00 | 403,719 | |
1/9/2017 | Leonard Bell | Director | Sell | 40,065 | $138.48 | $5,548,201.20 | 438,497 | |
1/5/2017 | Alvin S Parven | Director | Sell | 22,659 | $138.35 | $3,134,872.65 | 14,305 | |
12/12/2016 | John B Moriarty | EVP | Sell | 1,044 | $118.61 | $123,828.84 | 50,181 | |
12/9/2016 | Carsten Thiel | EVP | Sell | 2,308 | $130.00 | $300,040.00 | 30,433 | |
11/14/2016 | Heidi L Wagner | SVP | Sell | 59 | $115.10 | $6,790.90 | 31,936 | |
11/4/2016 | Leonard Bell | Director | Sell | 37,317 | $140.38 | $5,238,560.46 | 440,936 | |
10/31/2016 | Leonard Bell | Director | Sell | 1,300 | $135.28 | $175,864.00 | 406,589 | |
10/14/2016 | Carsten Thiel | EVP | Sell | 4,584 | $120.28 | $551,363.52 | 32,741 | |
10/3/2016 | Carsten Thiel | EVP | Sell | 29 | $122.41 | $3,549.89 | 37,325 | |
10/3/2016 | Heidi L Wagner | SVP | Sell | 120 | $122.41 | $14,689.20 | 31,995 | |
9/13/2016 | Carsten Thiel | EVP | Sell | 3,225 | $128.67 | $414,960.75 | 40,354 | |
9/9/2016 | Edward Miller | SVP | Sell | 367 | $128.32 | $47,093.44 | 16,519 | |
9/6/2016 | Carsten Thiel | EVP | Sell | 1,000 | $125.94 | $125,940.00 | 40,579 | |
9/2/2016 | Julie O'neill | EVP | Sell | 650 | $126.29 | $82,088.50 | 35,384 | |
8/30/2016 | Clare Carmichael | EVP | Sell | 1,000 | $127.76 | $127,760.00 | 38,577 | |
8/22/2016 | Alvin S Parven | Director | Sell | 15,000 | $136.53 | $2,047,950.00 | 6,373 | |
8/15/2016 | Alvin S Parven | Director | Sell | 700 | $135.51 | $94,857.00 | 6,373 | |
8/8/2016 | Clare Carmichael | EVP | Sell | 165 | $137.14 | $22,628.10 | 39,577 | |
8/8/2016 | David Hallal | CEO | Sell | 332 | $137.14 | $45,530.48 | 189,266 | |
8/8/2016 | Heidi L Wagner | SVP | Sell | 222 | $137.14 | $30,445.08 | 32,115 | |
8/8/2016 | Leonard Bell | Director | Sell | 1,010 | $137.14 | $138,511.40 | 405,289 | |
8/8/2016 | Vikas Sinha | CFO | Sell | 277 | $137.14 | $37,987.78 | 178,463 | |
6/13/2016 | John B Moriarty | EVP | Sell | 918 | $135.72 | $124,590.96 | 51,360 | |
5/16/2016 | Martin Mackay | EVP | Sell | 4,097 | $139.20 | $570,302.40 | 42,706 | |
5/13/2016 | Heidi L Wagner | SVP | Sell | 53 | $138.65 | $7,348.45 | 32,337 | |
4/1/2016 | David Hallal | CEO | Sell | 1,414 | $135.88 | $192,134.32 | 189,632 | |
2/29/2016 | Clare Carmichael | EVP | Sell | 1,312 | $138.91 | $182,249.92 | 41,054 | |
2/29/2016 | David Hallal | CEO | Sell | 2,014 | $138.93 | $279,805.02 | 193,026 | |
2/29/2016 | Edward Miller | SVP | Sell | 329 | $138.91 | $45,701.39 | 17,215 | |
2/29/2016 | Leonard Bell | Director | Sell | 3,995 | $138.92 | $554,985.40 | 742,222 | |
2/29/2016 | Vikas Sinha | CFO | Sell | 1,122 | $138.91 | $155,857.02 | 179,862 | |
2/8/2016 | David Hallal | CEO | Sell | 11,297 | $140.50 | $1,587,228.50 | 173,026 | |
2/8/2016 | Heidi L. Wagner | SVP | Sell | 2,108 | $140.93 | $297,080.44 | 29,937 | |
2/8/2016 | Julie O'neill | EVP | Sell | 2,858 | $141.83 | $405,350.14 | 30,348 | |
2/8/2016 | Leonard Bell | Director | Sell | 15,872 | $139.58 | $2,215,413.76 | 746,192 | |
2/8/2016 | Vikas Sinha | CFO | Sell | 6,547 | $140.04 | $916,841.88 | 171,862 | |
2/5/2016 | Edward Miller | SVP | Sell | 1,051 | $143.02 | $150,314.02 | 14,215 | |
12/29/2015 | Leonard Bell | Director | Sell | 35,000 | $190.66 | $6,673,100.00 | 749,259 | |
12/17/2015 | Leonard Bell | Director | Sell | 70,000 | $187.69 | $13,138,300.00 | 749,259 | |
12/11/2015 | Ann M Veneman | Director | Sell | 895 | $187.48 | $167,794.60 | 3,252 | |
12/11/2015 | John B. Moriarty | EVP | Sell | 943 | $182.73 | $172,314.39 | 41,340 | |
12/8/2015 | Leonard Bell | Director | Sell | 70,000 | $188.20 | $13,174,000.00 | 849,088 | |
12/8/2015 | Saqib Islam | EVP | Sell | 950 | $190.00 | $180,500.00 | 36,385 | |
11/25/2015 | Leonard Bell | Director | Sell | 35,000 | $181.89 | $6,366,150.00 | 919,088 | |
10/26/2015 | Saqib Islam | EVP | Sell | 1,558 | $168.44 | $262,429.52 | 38,310 | |
9/9/2015 | Leonard Bell | Director | Sell | 1,050 | $180.10 | $189,105.00 | 919,088 | |
6/18/2015 | Leonard Bell | Director | Sell | 27,835 | $179.63 | $5,000,001.05 | | |
3/19/2015 | Leonard Bell | CEO | Sell | 15,952 | $188.07 | $3,000,092.64 | | |
3/2/2015 | Julie O'neill | EVP | Sell | 11,665 | $101.49 | $1,183,880.85 | | |
3/2/2015 | Leonard Bell | CEO | Sell | 1,230 | $180.34 | $221,818.20 | | |
2/10/2015 | Clare Carmichael | EVP | Sell | 1,490 | $171.15 | $255,013.50 | | |
2/10/2015 | David Hallal | COO | Sell | 1,980 | $171.15 | $338,877.00 | | |
2/10/2015 | Leonard Bell | CEO | Sell | 5,740 | $171.15 | $982,401.00 | | |
2/10/2015 | Vikas Sinha | CFO | Sell | 1,985 | $171.15 | $339,732.75 | | |
2/9/2015 | Clare Carmichael | EVP | Sell | 1,665 | $173.75 | $289,293.75 | | |
2/9/2015 | David Hallal | COO | Sell | 2,920 | $173.93 | $507,875.60 | | |
2/9/2015 | Leonard Bell | CEO | Sell | 8,660 | $173.98 | $1,506,666.80 | | |
2/9/2015 | Vikas Sinha | CFO | Sell | 2,703 | $174.18 | $470,808.54 | | |
2/4/2015 | David Hallal | COO | Sell | 1,373 | $174.18 | $239,149.14 | | |
2/4/2015 | Leonard Bell | CEO | Sell | 5,223 | $174.29 | $910,316.67 | | |
2/4/2015 | Vikas Sinha | CFO | Sell | 1,571 | $174.19 | $273,652.49 | | |
12/18/2014 | David Hallal | COO | Sell | 5,494 | $182.03 | $1,000,072.82 | | |
12/18/2014 | Leonard Bell | CEO | Sell | 30,415 | $179.73 | $5,466,487.95 | | |
12/18/2014 | Vikas Sinha | CFO | Sell | 5,493 | $182.08 | $1,000,165.44 | | |
12/9/2014 | Leonard Bell | CEO | Sell | 133,320 | $198.26 | $26,432,023.20 | | |
12/4/2014 | Clare Carmichael | SVP | Sell | 10,000 | $196.25 | $1,962,500.00 | | |
12/4/2014 | William R Keller | Director | Sell | 5,000 | $196.25 | $981,250.00 | | |
12/3/2014 | Vikas Sinha | CFO | Sell | 75,000 | $198.96 | $14,922,000.00 | | |
11/3/2014 | David Hallal | COO | Sell | 30,000 | $190.01 | $5,700,300.00 | | |
11/3/2014 | Martin Mackay | EVP | Sell | 9,375 | $191.52 | $1,795,500.00 | | |
11/3/2014 | Saqib Islam | SVP | Sell | 28,125 | $190.50 | $5,357,812.50 | | |
11/3/2014 | Vikas Sinha | CFO | Sell | 49,307 | $192.63 | $9,498,007.41 | | |
10/27/2014 | John B Moriarty | SVP | Sell | 10,000 | $189.49 | $1,894,900.00 | | |
10/27/2014 | Stephen P Squinto | EVP | Sell | 5,910 | $188.58 | $1,114,507.80 | | |
10/6/2014 | John B Moriarty | SVP | Sell | 10,000 | $179.00 | $1,790,000.00 | | |
10/3/2014 | Stephen P Squinto | EVP | Sell | 10,025 | $172.41 | $1,728,410.25 | | |
9/26/2014 | Leonard Bell | CEO | Sell | 60,000 | $165.12 | $9,907,200.00 | | |
9/24/2014 | Stephen P Squinto | EVP | Sell | 76 | $159.50 | $12,122.00 | | |
9/18/2014 | Leonard Bell | CEO | Sell | 44,435 | $160.60 | $7,136,261.00 | | |
9/10/2014 | Leonard Bell | CEO | Sell | 12,199 | $165.38 | $2,017,470.62 | | |
9/8/2014 | Leonard Bell | CEO | Sell | 197,801 | $165.32 | $32,700,461.32 | | |
8/27/2014 | Leonard Bell | CEO | Sell | 5,912 | $169.17 | $1,000,133.04 | | |
8/25/2014 | Andreas Rummelt | Director | Sell | 5,052 | $170.53 | $861,517.56 | | |
8/15/2014 | Leonard Bell | CEO | Sell | 70,000 | $167.99 | $11,759,300.00 | | |
8/13/2014 | Leonard Bell | CEO | Sell | 105,000 | $160.71 | $16,874,550.00 | | |
8/12/2014 | Leonard Bell | CEO | Sell | 80,458 | $160.16 | $12,886,153.28 | | |
8/4/2014 | David Hallal | EVP | Sell | 1,349 | $158.00 | $213,142.00 | | |
8/4/2014 | Leonard Bell | CEO | Sell | 5,145 | $157.88 | $812,292.60 | | |
8/4/2014 | Vikas Sinha | CFO | Sell | 1,525 | $157.82 | $240,675.50 | | |
7/30/2014 | Leonard Bell | CEO | Sell | 127,289 | $162.93 | $20,739,196.77 | | |
7/29/2014 | Leonard Bell | CEO | Sell | 1,200 | $164.93 | $197,916.00 | | |
7/28/2014 | Leonard Bell | CEO | Sell | 105,600 | $162.38 | $17,147,328.00 | | |
6/20/2014 | Leonard Bell | CEO | Sell | 90,280 | $163.60 | $14,769,808.00 | | |
6/12/2014 | Martin Mackay | EVP | Sell | 25,000 | $166.42 | $4,160,500.00 | | |
6/5/2014 | William R Keller | Director | Sell | 3,425 | $170.00 | $582,250.00 | | |
5/27/2014 | Leonard Bell | CEO | Sell | 70,000 | $166.16 | $11,631,200.00 | | |
5/20/2014 | Leonard Bell | CEO | Sell | 70,000 | $155.96 | $10,917,200.00 | 1,032,331 | |
5/14/2014 | Martin Mackay | EVP | Sell | 3,574 | $160.85 | $574,877.90 | 24,426 | |
5/13/2014 | Alvin Parven | Director | Sell | 12,276 | $160.78 | $1,973,735.28 | 4,840 | |
4/29/2014 | Leonard Bell | CEO | Sell | 70,000 | $156.20 | $10,934,000.00 | 1,032,331 | |
2/10/2014 | Stephen Squinto | EVP | Sell | 7,055 | $158.04 | $1,114,972.20 | 101,308 | |
2/7/2014 | David Hallal | EVP | Sell | 1,620 | $155.57 | $252,023.40 | 113,965 | |
2/7/2014 | Frank Wright | SVP | Sell | 1,098 | $155.57 | $170,815.86 | 19,670 | |
2/7/2014 | Joseph Madri | Director | Sell | 30,000 | $159.00 | $4,770,000.00 | 179,217 | |
2/7/2014 | Leonard Bell | CEO | Sell | 4,620 | $155.56 | $718,687.20 | 986,696 | |
2/4/2014 | Leonard Bell | CEO | Sell | 11,790 | $154.50 | $1,821,555.00 | 963,276 | |
2/4/2014 | Stephen Squinto | EVP | Sell | 36,989 | $155.12 | $5,737,733.68 | 94,818 | |
2/4/2014 | Vikas Sinha | CFO | Sell | 3,552 | $154.47 | $548,677.44 | 129,775 | |
1/29/2014 | Leonard Bell | CEO | Sell | 2,660 | $133.81 | $355,934.60 | 975,066 | |
1/29/2014 | Stephen Squinto | EVP | Sell | 1,118 | $133.31 | $149,040.58 | 103,068 | |
1/22/2014 | Leonard Bell | CEO | Sell | 156,436 | $140.80 | $22,026,188.80 | 977,726 | |
1/10/2014 | Leonard Bell | CEO | Sell | 19,155 | $134.98 | $2,585,541.90 | 1,031,957 | |
12/19/2013 | Leonard Bell | CEO | Sell | 175,000 | $126.38 | $22,116,500.00 | 1,031,957 | |
10/28/2013 | Stephen P Squinto | EVP | Sell | 41,037 | $124.06 | $5,091,050.22 | | |
10/28/2013 | Vikas Sinha | CFO | Sell | 50,000 | $122.97 | $6,148,500.00 | | |
9/16/2013 | Joseph Madri | Director | Sell | 30,000 | $115.00 | $3,450,000.00 | 179,217 | |
9/16/2013 | Leonard Bell | CEO | Sell | 3,500 | $115.00 | $402,500.00 | 1,026,293 | |
9/13/2013 | Stephen Squinto | EVP | Sell | 1,000 | $114.37 | $114,370.00 | | |
9/4/2013 | Leonard Bell | CEO | Sell | 1,850 | $110.07 | $203,629.50 | | |
9/3/2013 | Leonard Bell | CEO | Sell | 33,150 | $110.19 | $3,652,798.50 | 1,003,519 | |
8/30/2013 | Clare Carmichael | SVP | Sell | 1,237 | $107.58 | $133,076.46 | 9,463 | |
8/16/2013 | Leonard Bell | CEO | Sell | 140,000 | $106.08 | $14,851,200.00 | 1,036,669 | |
8/5/2013 | Leonard Bell | CEO | Sell | 2,919 | $116.87 | $341,143.53 | 1,176,669 | |
8/2/2013 | Stephen P Squinto | EVP | Sell | 14,125 | $115.33 | $1,629,036.25 | | |
7/30/2013 | Leonard Bell | CEO | Sell | 212,737 | $114.62 | $24,383,914.94 | | |
7/30/2013 | Stephen P Squinto | EVP | Sell | 1,120 | $110.86 | $124,163.20 | | |
7/12/2013 | David Hallal | EVP | Sell | 50,000 | $120.00 | $6,000,000.00 | | |
7/1/2013 | Stephen P Squinto | EVP | Sell | 44,125 | $94.97 | $4,190,551.25 | | |
5/22/2013 | R Douglas Norby | Director | Sell | 40,000 | $102.77 | $4,110,800.00 | | |
5/20/2013 | William R Keller | Director | Sell | 9,770 | $103.00 | $1,006,310.00 | | |
5/14/2013 | Leonard Bell | CEO | Sell | 31,113 | $105.74 | $3,289,888.62 | | |
5/13/2013 | Leonard Bell | CEO | Sell | 41,220 | $100.85 | $4,157,037.00 | | |
4/10/2013 | Leonard Bell | CEO | Sell | 26,700 | $100.24 | $2,676,408.00 | | |
2/4/2013 | Leonard Bell | CEO | Sell | 11,880 | $96.27 | $1,143,687.60 | | |
2/4/2013 | Stephen P Squinto | EVP | Sell | 2,572 | $95.68 | $246,088.96 | | |
2/4/2013 | Vikas Sinha | CFO | Sell | 3,483 | $95.81 | $333,706.23 | | |
1/15/2013 | Leonard Bell | CEO | Sell | 35,000 | $98.58 | $3,450,300.00 | | |
10/31/2012 | Patrice Coissac | SVP | Sell | 84,764 | $91.16 | $7,727,086.24 | | |
(Data available from 1/1/2013 forward)
Alexion Pharmaceuticals (NASDAQ ALXN) News Headlines
Source: |
|
Date | Headline |
---|
 | Alexion Pharmaceuticals (ALXN) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 19 at 11:46 AM |
 | Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, Alder Biopharma, and Alexion Pharma www.bizjournals.com - April 19 at 8:14 AM |
 | Q1 2018 EPS Estimates for Alexion Pharmaceuticals Boosted by Analyst (ALXN) www.americanbankingnews.com - April 19 at 6:28 AM |
 | Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer www.businesswire.com - April 18 at 8:15 AM |
 | B.Riley/FBR Downgrades Alexion Pharmaceuticals (ALXN) to Neutral Following Acquisition of Wilson Therapeutics www.streetinsider.com - April 18 at 8:15 AM |
 | Alexion Pharmaceuticals (ALXN) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 18 at 3:28 AM |
 | Alexion Pharmaceuticals (ALXN) Upgraded at BidaskClub www.americanbankingnews.com - April 16 at 12:03 PM |
 | Alexion Pharmaceuticals Forecasted to Earn Q1 2018 Earnings of $1.25 Per Share (ALXN) www.americanbankingnews.com - April 16 at 1:44 AM |
 | Alexion Pharmaceuticals (ALXN) Upgraded to "Strong-Buy" at Zacks Investment Research www.americanbankingnews.com - April 14 at 10:19 AM |
 | Alexion Spruces Up Its Pipeline With $855 Million Buy Of Rare Disease Drug Maker seekingalpha.com - April 13 at 8:18 AM |
 | Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics finance.yahoo.com - April 13 at 8:18 AM |
 | Alexion Pharmaceuticals (ALXN) PT Raised to $165.00 at Nomura www.americanbankingnews.com - April 12 at 10:46 AM |
 | Your Daily Pharma Scoop: Paratek Update, Alexion Acquisition, Arrowhead Data seekingalpha.com - April 12 at 8:33 AM |
 | Alexion Joins The Biotech M&A Bonanza seekingalpha.com - April 12 at 8:33 AM |
 | Alexion Pharmaceuticals (ALXN) PT Raised to $113 at Jefferies on Plan to Acqurie WTX101 www.streetinsider.com - April 11 at 5:33 PM |
 | Why Alexion Pharmaceuticals Inc (NASDAQ:ALXN) May Not Be As Efficient As Its Industry finance.yahoo.com - April 11 at 5:33 PM |
 | How Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva finance.yahoo.com - April 11 at 5:33 PM |
 | Alexion Pharma To Buy Sweden's Wilson Therapeutics For $855 Mln In Cash www.nasdaq.com - April 11 at 8:29 AM |
 | Biotech M&A rolls on as Alexion snaps up Wilson for $855 million www.reuters.com - April 11 at 8:29 AM |
 | Alexion Pharma (ALXN) Agrees to Acquire Wilson Therapeutics for $855M www.streetinsider.com - April 11 at 8:29 AM |
 | Alexion to Acquire Wilson Therapeutics finance.yahoo.com - April 11 at 8:29 AM |
 | Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln finance.yahoo.com - April 11 at 8:29 AM |
![[$$] Alexion Makes Bid for Swedens Wilson Therapeutics [$$] Alexion Makes Bid for Swedens Wilson Therapeutics](/images/news-sites/YahooFinance.jpg) | [$$] Alexion Makes Bid for Sweden's Wilson Therapeutics finance.yahoo.com - April 11 at 8:29 AM |
 | Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln finance.yahoo.com - April 11 at 8:29 AM |
 | BidaskClub Lowers Alexion Pharmaceuticals (ALXN) to Buy www.americanbankingnews.com - April 10 at 4:29 PM |
 | Alexion Pharmaceuticals (ALXN) Upgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - April 10 at 12:01 PM |
 | $919.03 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter www.americanbankingnews.com - April 10 at 2:36 AM |
 | Alexion Pharmaceuticals, Inc. Is Researching a Turnaround investorplace.com - April 9 at 1:48 PM |
 | Alexion Pharmaceuticals (ALXN) Stock Rating Upgraded by JPMorgan Chase www.americanbankingnews.com - April 9 at 1:19 PM |
 | Analysts Anticipate Alexion Pharmaceuticals, Inc. (ALXN) to Announce $1.48 Earnings Per Share www.americanbankingnews.com - April 8 at 7:15 PM |
 | Alexion Pharmaceuticals (ALXN) PT Lowered to $159.00 www.americanbankingnews.com - April 5 at 9:36 PM |
![[$$] Investors smart at ailing pharma deals [$$] Investors smart at ailing pharma deals](/images/news-sites/YahooFinance.jpg) | [$$] Investors smart at ailing pharma deals finance.yahoo.com - April 5 at 10:09 AM |
 | Alexion Pharmaceuticals (ALXN) Upgraded to "Buy" by Zacks Investment Research www.americanbankingnews.com - April 2 at 8:08 PM |
 | Alexion Pharmaceuticals (ALXN) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 2 at 12:26 PM |
 | Alexion Pharmaceuticals (ALXN) vs. Roche (RHHBY) Financial Comparison www.americanbankingnews.com - March 30 at 3:24 AM |
 | Alexion Pharmaceuticals (ALXN) Cut to "Strong Sell" at BidaskClub www.americanbankingnews.com - March 27 at 5:10 PM |
 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. finance.yahoo.com - March 27 at 8:26 AM |
 | Alexion Pharmaceuticals, Inc. (ALXN) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - March 26 at 1:34 AM |
 | Alexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $919.03 Million www.americanbankingnews.com - March 24 at 2:58 AM |
 | A Look at Incyte’s Valuation in March 2018 finance.yahoo.com - March 23 at 8:17 AM |
 | Alexion Pharmaceuticals (ALXN) Upgraded to Sell by BidaskClub www.americanbankingnews.com - March 17 at 2:18 PM |
 | Credit Suisse Group Boosts Alexion Pharmaceuticals (ALXN) Price Target to $149.00 www.americanbankingnews.com - March 16 at 12:38 PM |
 | Pre-Market Most Active for Mar 15, 2018 : ALXN, PTI, AQUA, BABA, SBGL, QQQ, HGV, ERIC, MU, HMY, XT, DG - Nasdaq www.nasdaq.com - March 16 at 8:17 AM |
 | Alexion shares jump 11% premarket on news of positive trial of treatment for rare blood disorder - MarketWatch www.marketwatch.com - March 16 at 8:17 AM |
 | Deutsche Bank Analysts Give Alexion Pharmaceuticals (ALXN) a $161.00 Price Target www.americanbankingnews.com - March 15 at 9:26 PM |
 | Nomura Raises Alexion Pharmaceuticals (ALXN) Price Target to $156.00 www.americanbankingnews.com - March 15 at 7:42 PM |
 | Alexion Pharmaceuticals (ALXN) PT Set at $160.00 by Robert W. Baird www.americanbankingnews.com - March 15 at 7:06 PM |
 | Alexion Wins Big in Late-Stage Trial www.msn.com - March 15 at 6:14 PM |
 | Alexion Pharmaceuticals (ALXN) Updates On ALXN1210 PNH Naive Phase 3 Study Results - Slideshow seekingalpha.com - March 15 at 6:14 PM |
 | Alexion shares jump 11% premarket on news of positive trial of treatment for rare blood disorder finance.yahoo.com - March 15 at 6:14 PM |
Alexion Pharmaceuticals (NASDAQ:ALXN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alexion Pharmaceuticals (NASDAQ:ALXN) Income Statement, Balance Sheet and Cash Flow Statement
Alexion Pharmaceuticals (NASDAQ ALXN) Stock Chart for Thursday, April, 19, 2018
Loading chart…